DK0752876T3 - Monoklonale antistoffer, som binder til tumorafstødningsantigen-precursor MAGE-1, rekombinant MAGE-1 samt immunogene peptider afledt af MAGE-1 - Google Patents

Monoklonale antistoffer, som binder til tumorafstødningsantigen-precursor MAGE-1, rekombinant MAGE-1 samt immunogene peptider afledt af MAGE-1

Info

Publication number
DK0752876T3
DK0752876T3 DK95907978T DK95907978T DK0752876T3 DK 0752876 T3 DK0752876 T3 DK 0752876T3 DK 95907978 T DK95907978 T DK 95907978T DK 95907978 T DK95907978 T DK 95907978T DK 0752876 T3 DK0752876 T3 DK 0752876T3
Authority
DK
Denmark
Prior art keywords
mage
monoclonal antibodies
bind
tumor rejection
recombinant
Prior art date
Application number
DK95907978T
Other languages
Danish (da)
English (en)
Inventor
Yao-Tseng Chen
Elisabeth Stockert
Yachi Chen
Pilar Garin-Chesa
Der Bruggen Pierre Van
Thierry Boon-Falleur
Lloyd J Old
Wolfgang J Oncology Res Rettig
Original Assignee
Sloan Kettering Inst Cancer
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer, Ludwig Inst Cancer Res filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of DK0752876T3 publication Critical patent/DK0752876T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK95907978T 1994-02-01 1995-01-05 Monoklonale antistoffer, som binder til tumorafstødningsantigen-precursor MAGE-1, rekombinant MAGE-1 samt immunogene peptider afledt af MAGE-1 DK0752876T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/190,411 US5541104A (en) 1991-05-23 1994-02-01 Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
PCT/US1995/000095 WO1995020974A1 (en) 1994-02-01 1995-01-05 Monoclonal anbibodies which bind to tumor rejection antigen precursor mage-1, recombinant mage-1, and mage-1 derived immunogenic peptides

Publications (1)

Publication Number Publication Date
DK0752876T3 true DK0752876T3 (da) 2002-05-21

Family

ID=22701236

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95907978T DK0752876T3 (da) 1994-02-01 1995-01-05 Monoklonale antistoffer, som binder til tumorafstødningsantigen-precursor MAGE-1, rekombinant MAGE-1 samt immunogene peptider afledt af MAGE-1

Country Status (16)

Country Link
US (2) US5541104A (de)
EP (1) EP0752876B1 (de)
JP (1) JPH09511389A (de)
CN (1) CN1145032A (de)
AT (1) ATE215831T1 (de)
AU (1) AU686314B2 (de)
CA (1) CA2182369A1 (de)
DE (1) DE69526339T2 (de)
DK (1) DK0752876T3 (de)
ES (1) ES2174931T3 (de)
FI (1) FI963033A (de)
NO (1) NO963120L (de)
NZ (1) NZ279377A (de)
PT (1) PT752876E (de)
WO (1) WO1995020974A1 (de)
ZA (1) ZA95786B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40089E1 (en) * 1991-05-23 2008-02-19 Ludwig Institute For Cancer Research Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
KR0185334B1 (ko) * 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
US5908778A (en) 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
WO1999030734A1 (en) * 1997-12-18 1999-06-24 G.D. Searle & Co. Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity
CA2584482C (en) 1998-02-05 2012-03-27 Smithkline Beecham Biologicals S.A. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
US7157091B1 (en) 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
EP1377680B1 (de) 2001-04-12 2011-10-05 Imperial Innovations Limited Diagnose und behandlung von brustkrebs mit scn5a
PT1496939E (pt) 2002-04-09 2007-11-22 Sanofi Pasteur Ltd ''ácido nucleico de cea modificado e vectores de expressão''
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
FR2889959A1 (fr) * 2005-09-01 2007-03-02 Commissariat Energie Atomique Epitopes t cd4+ des antigenes mage-a restreints a hla-dp4 et leurs applications
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8097256B2 (en) * 2006-09-28 2012-01-17 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
US10137182B2 (en) 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
HRP20220230T1 (hr) 2017-01-05 2022-04-29 Kahr Medical Ltd. Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
US20210187023A1 (en) 2017-06-27 2021-06-24 The Trustees Of Princeton University Compositions And Methods For Enhancing Immunotherapy
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
WO2019145509A1 (en) 2018-01-26 2019-08-01 Cambridge Enterprise Limited Peptide exchange protein
KR20210044220A (ko) 2018-07-11 2021-04-22 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
WO2020041662A1 (en) 2018-08-24 2020-02-27 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
KR20220044284A (ko) 2019-07-11 2022-04-07 카 메디컬 리미티드 이종이량체 및 이의 사용방법
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
US20230048719A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
WO2023083864A1 (en) 2021-11-09 2023-05-19 T-Knife Gmbh Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
KR950003005B1 (ko) * 1992-04-09 1995-03-29 주식회사 진흥전자 자동소변세척기
DE4224542A1 (de) * 1992-07-24 1994-01-27 Deutsches Krebsforsch Verfahren zur Herstellung von monoklonalen MHC Klasse I-puls-Peptid-restringierten Antikörpern

Also Published As

Publication number Publication date
EP0752876A4 (de) 1999-07-07
WO1995020974A1 (en) 1995-08-10
ZA95786B (en) 1995-10-09
DE69526339T2 (de) 2003-01-02
CN1145032A (zh) 1997-03-12
ATE215831T1 (de) 2002-04-15
US5843448A (en) 1998-12-01
AU686314B2 (en) 1998-02-05
AU1597995A (en) 1995-08-21
NO963120L (no) 1996-09-30
EP0752876A1 (de) 1997-01-15
NO963120D0 (no) 1996-07-26
EP0752876B1 (de) 2002-04-10
JPH09511389A (ja) 1997-11-18
PT752876E (pt) 2002-09-30
ES2174931T3 (es) 2002-11-16
DE69526339D1 (de) 2002-05-16
US5541104A (en) 1996-07-30
FI963033A0 (fi) 1996-07-31
NZ279377A (en) 1997-07-27
FI963033A (fi) 1996-07-31
CA2182369A1 (en) 1995-08-10

Similar Documents

Publication Publication Date Title
DK0752876T3 (da) Monoklonale antistoffer, som binder til tumorafstødningsantigen-precursor MAGE-1, rekombinant MAGE-1 samt immunogene peptider afledt af MAGE-1
DE69433663D1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
DE69429095D1 (de) Humanisierte antikoerper
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
PT994903E (pt) Metodos e composicoes para glicoproteinas galactosiladas
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
TR199900267T2 (xx) GnRH-L�kotoksin kimeralar�.
ATE177758T1 (de) Synthetische peptide, antikörper dagegen und ihre verwendung
WO1998022510A3 (en) Methods for the production of chicken monoclonal antibodies
HUP9903770A2 (hu) Eljárások és készítmények többepitópos antigének konformációjának megváltoztatására immunválasz kiváltása céljából
DE69634092D1 (de) Herstellung von antikörpern
AU6276301A (en) A variable region of the monoclonal antibody against the hbv s-surface antigen and a gene encoding the same
DE69922834D1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
KR900701318A (ko) 항-사람 고분자량- 흑색종 관련 항원에 대한 항-이디오 타입 항체
DE69224134D1 (de) Monoklonale Antikörper gegen Hepatitis-C-Virus
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
DK0831881T3 (da) CETP til forøgelse af HDL-cholesterolniveau
DE60216906D1 (de) Anti-pilyrosporum ovale igy und dessen verwendung
ATE340863T1 (de) Pseudomonas exotoxin a-ähnliche chimerische immunogene zum auslösen einer sekretorischen iga- vermittelten immunantwort
NO962827L (no) Monoklonale antistoffer mot antigener uttrykt av hematopoietider facilitatoriske celler
DK0472706T3 (da) Induktion af beskyttelse mod viral infektion
BR0007827A (pt) Anticorpos e fragmento fv que reconhecemantìgeno ior c2
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
HUP0001270A2 (en) Compositions and methods for the treatment and diagnosis of breast cancer